Bleed reduction observed in real-world SHL switches¹

Patients who switched to ALPROLIX^® prophylaxis saw a reduction in ABRs regardless of prior factor IX therapy or treatment regimen¹

• The median ABR with ALPROLIX prophylaxis was less than half that of patients’ prior SHL prophylaxis (4.8 vs 2; n=13)
• 81% of patients (n=26/32) who switched to ALPROLIX prophylaxis from SHL prophylaxis were able to lengthen their dosing interval
• The median duration on ALPROLIX was 2.7 (0.5-5) years
• Patients who switched to ALPROLIX prophylaxis from prior SHL prophylaxis saw an ~50% reduction in weekly factor consumption (n=32)
  - Median baseline consumption was 116 IU/kg on prior SHL therapy, with a reduction to 60 IU/kg at first infusion of ALPROLIX

Study design¹

• Data are from a multicenter, retrospective chart review of patients with hemophilia B (n=64) aged 2 to 78 years who had received ALPROLIX prophylaxis or on-demand treatment for ≥6 months across 6 sites in the United States
• The median duration on ALPROLIX was 2.7 (0.5-5) years
• Some of the data were collected while the patients were in the B-LONG, Kids B-LONG, and B-YOND studies; however, most data were collected after study termination

Study limitations¹

• These data are limited by the retrospective nature of the chart review; small sample sizes; the availability, completeness, and accuracy of medical charts; and the variability of the information collected by different observers
• Data are presented using descriptive statistics; therefore, extrapolation of results to patients outside the study population may be limited

*Patients could be on prior SHL prophylaxis treatment or SHL on-demand treatment before switching to ALPROLIX prophylaxis.

Data are not from a head-to-head study. No head-to-head studies were conducted to assess the safety or efficacy of ALPROLIX compared with SHL products.